NCT01894373View on ClinicalTrials.gov

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
PsoriasisAdoptive Immunotherapy
Interventions
DRUG

Adoptive Immunotherapy

Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells

BIOLOGICAL

CIK

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT01894373 - Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis | Biotech Hunter | Biotech Hunter